Eli Lilly crushes Q1 estimates, raises full-year outlook as GLP-1 sales surge

Eli Lilly and Co (NYSE:LLY) reported stronger-than-expected first-quarter 2026 results driven by surging demand for its diabetes and obesity treatments...